DeNucci, GilbertoWilkinson, TomSverdloff, CarlosBadadopulos, TainahWoodcock, AshleyShute, JanisGuazelli, Pedro RenatoGerbase, Luis FredericoMourao, Paulo A SSingh, Davevan Haren, FrankPage, Clive2024-12-162024-12-161094-5539https://hdl.handle.net/1885/733731445There is a strong scientific rationale to use nebulised unfractionated heparin (UFH) in treating patients with COVID-19. This pilot study investigated whether nebulised UFH was safe and had any impact on mortality, length of hospitalisation and clinical progression, in the treatment of hospitalised patients with COVID-19. This parallel group, open label, randomised trial included adult patients with confirmed SARS-CoV-2 infection admitted to two hospitals in Brazil. One hundred patients were planned to be randomised to either “standard of care” (SOC) or SOC plus nebulized UFH. The trial was stopped after randomisation of 75 patients due to falling COVID-19 hospitalisation rates. Significance tests were 1-sided test (10% significance level). The key analysis populations were intention to treat (ITT) and modified ITT (mITT) which excluded (from both arms) subjects admitted to ITU or who died within 24 h of randomisation. In the ITT population (n = 75), mortality was numerically lower for nebulised UFH (6 out of 38 patients; 15.8%) versus SOC (10 out of 37 patients; 27.0%), but not statistically significant; odds ratio (OR) 0.51, p = 0.24. However, in the mITT population, nebulised UFH reduced mortality (OR 0.2, p = 0.035). Length of hospital stay was similar between groups, but at day 29, there was a greater improvement in ordinal score following treatment with UFH in the ITT and mITT populations (p = 0.076 and p = 0.012 respectively), while mechanical ventilation rates were lower with UFH in the mITT population (OR 0.31; p = 0.08). Nebulised UFH did not cause any significant adverse events. In conclusion, nebulised UFH added to SOC in hospitalised patients with COVID-19 was well tolerated and showed clinical benefit, particularly in patients who received at least 6 doses of heparin.The authors acknowledge the generous financial support of the Jon Moulton Charity Trust that made this trial possible and the help of Dr Helen Critchley.application/pdfen-AU© 2023 Published by Elsevier Ltd.COVID-19SARS-CoV-2Inhaled heparinNebulised heparinUnfractionated heparinRespiratory failureRandomised controlled trial202310.1016/j.pupt.2023.1022122024-01-21